TP53 and cancer: Finally, various drug resistant cell models, including the p53 null RKO model, highly ABCB1 overexpressing KB-C-1 cells as well as cell lines with acquired cisplatin and oxaliplatin resistance appeared equally sensitive to 13-induced in vitro anti-cancer effects according to MTT data (Table S1).